Delonix Bioworks and Zhifei Lvzhu Collaborate on the Application of Synthetic Biology Technology in the Vaccine Field
Chongqing, China, January 02, 2024 – Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (“Zhifei Lvzhu”), a wholly owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd., today announced that it had signed a Vaccine Development and License Agreement with the China based company Delonix Bioworks Co., Ltd. (“Delonix”). The two parties will jointly engage in in-depth cooperation on the application of synthetic biology technology in the vaccine field, based on Zhifei Lvzhu’s innovative vaccine development platform at its incubation center and Delonix's synthetic biology vaccine technology platform. By leveraging their complementary strengths in the upstream and downstream vaccine sectors, they will jointly advance the application of synthetic biology technology in the field of bacterial vaccines. Under the terms of the agreement, Zhifei Lvzhu will receive an exclusive license to the cooperation project, inlcuding the rights to research, develop, mannufacture, and commercialize within the designated regions.
Mr. Du Lin, Executive Director of Zhifei Lvzhu, commented: "ZhiFei Lvzhu specializes in developing innovative human vaccines, with our Innovation Incubation Center focused on cutting-edge technologies in the vaccine industry. We aim to address industry challenges and provide technical support for the development of more innovative products. Through our R&D collaboration with Deloinx, we will jointly explore the frontier applications of synthetic biology technology in the vaccine field and accelerate the innovative development for the next generation of bacterial vaccines."
Dr. Qiubin Lin, Founder and CEO of Delonix, commented, "We are pleased to collaborate with Zhifei Lvzhu. Both Zhifei Lvzhu and Delonix share a strong alignment in our vision and approach to vaccine innovation and development. We believe that through our complementary strengths, we can accelerate the application of synthetic biology technology in the field of bacterial vaccines."
About Beijing Zhifei Lvzhu
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. is a leading human vaccine enterprise in China, specializing in the research and development, production and sales of vaccines targeting meningitis, pneumonia, diphtheria, tetanus & pertussis, and diarrhea (shigellosis). The company, located at Yi Zhuang, Zhongguancun Life Science Park, is equipped with advanced R&D center for novel vaccine development and has GMP certified modern vaccine production base. After nearly 20 years of innovation and development, Zhifei Lvzhu has successively won honorary titles including Beijing G20 Project Innovation Leading Enterprise, Beijing Small and Medium-sized Enterprise with Specialization and Innovation, Beijing Patent Pilot Enterprise, Zhongguancun High-tech Enterprise, etc. Since 2008, Zhifei Lvzhu has produced and supplied more than 110 million doses of vaccines to people needed worldwide. For more information, please visit http://www.vaccine.com.cn.
About Delonix
Delonix Bioworks is a leading synthetic biology company specializing in innovative vaccine development. It has advanced gene editing and modification capabilities for over ten pathogens, making it a global leader in genetically engineered vaccine development. The company has significant expertise in engineering key vaccine components, such as polysaccharides, detoxified LPS, and bacterial outer membrane vesicles (OMVs).
The company has launched two proprietary synthetic vaccine platforms: ProBVax, an engineered whole-cell vaccine platform, and BioDVax, an engineered subunit vaccine platform. With these two innovative platforms, Delonix has successfully developed a range of world-class innovative vaccine pipelines, several of which are expected to reach the clinical stage within the next two years.
Since 2021, Delonix has received recognition from various organizations, including the Boehringer Ingelheim Innovation Prize (Champion) and the Venture 50 “New Seed List Top 50”. For more information, please visit: https://delonixbio.com.